Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis (COLCHIVAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04008316
Recruitment Status : Not yet recruiting
First Posted : July 5, 2019
Last Update Posted : November 18, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Immunoglobulin A vasculitis (IgA-V), formerly called Henoch-Schönlein purpura, is an immune vasculitis. Relapses are frequent (30%) and most of the time cutaneous (90%). Cutaneous involvement in adults is more severe (haemorrhagic blister or necrotic skin lesions) and more extensive than in children. Quality of life can be significantly altered by frequent cutaneous relapses. Colchicine, historically used for gout flares, is known to be an " old " low cost drug inducing very few adverse events. This molecule inhibits polymorphonuclear cell-chemotaxis to the site of inflammation explaining colchicine clinical efficacy in diseases such as Familial Mediterranean Fever or Behçet disease. Efficacy of colchicine has also been reported in cutaneous leukocytoclastic vasculitis including IgA-V, but without clinical studies supporting this attitude.

Condition or disease Intervention/treatment Phase
IgA Vasculitis Drug: Colchicine Phase 3

Detailed Description:
Immunoglobulin A vasculitis (IgA-V), formerly called Henoch-Schönlein purpura, is an immune vasculitis. Relapses are frequent (30%) and most of the time cutaneous (90%). Cutaneous involvement in adults is more severe (haemorrhagic blister or necrotic skin lesions) and more extensive than in children. Quality of life can be significantly altered by frequent cutaneous relapses. Colchicine, historically used for gout flares, is known to be an " old " low cost drug inducing very few adverse events. It inhibits polymorphonuclear cell-chemotaxis to the site of inflammation explaining colchicine clinical efficacy in diseases such as Familial Mediterranean Fever or Behçet disease. Efficacy of colchicine has also been reported in cutaneous leukocytoclastic vasculitis including IgA-V, but without clinical studies supporting this attitude To assess efficacy of colchicine in adult's cutaneous IgA-V, the investigators conduct a prospective, controlled, double blind, randomized clinical trial, national, multicenter and multidisciplinary (internal medicine, nephrology and dermatology): colchicine 1mg/day versus placebo for 6 months, with a 12 months total follow-up. The primary objective is to evaluate efficacy of colchicine versus placebo to prevent cutaneous relapses, 6 months after inclusion, in adult patients with cutaneous IgA vasculitis alone or associated with non-severe digestive or renal involvement.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 264 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: prospective, controlled, double blind, randomized clinical trial: colchicine 1mg/day versus placebo for 6 months, with a 12 months total follow-up.
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis
Estimated Study Start Date : November 18, 2019
Estimated Primary Completion Date : November 18, 2022
Estimated Study Completion Date : May 18, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vasculitis
Drug Information available for: Colchicine

Arm Intervention/treatment
Experimental: colchicine 1mg/day
Colchicine per os: 1 tablet (1mg) / day during 6 months
Drug: Colchicine
colchicine 1mg/day

Placebo Comparator: placebo
placebo 1 tablet / day during 6 months
Drug: Colchicine
colchicine 1mg/day




Primary Outcome Measures :
  1. the occurrence of the first cutaneous skin relapse [ Time Frame: 6 months ]
    Cutaneous skin relapse is defined by reappearance of palpable purpura with lower limb predominance and not related to thrombocytopenia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years and < 85 years
  2. IgA-V recently diagnosed (< 20 days since skin biopsy) and defined by :

    • Histologically proven small vessels vasculitis with IgA deposits IgA Vasculitis
    • Purpura and/or involvement of at least one organ among kidney, joint, or intestinal tract

Exclusion Criteria:

  1. Severe renal IgA vasculitis:

    • impaired renal function, defined as an eGFR < 60 ml per minute per 1.73 m2 (MDRD or CKD-EPI formula)
    • proteinuria/creatinuria> 1g/g
    • Uncontrolled blood pressure (Systolic blood pressure > 170 mmHg, diastolic blood pressure > 100 mmHg)
  2. Severe digestive IgA vasculitis:

    • intussusception
    • massive gastrointestinal haemorrhage (requiring transfusion)
    • intestinal ischemia
    • perforation
    • abdominal pain persisting more than one day (EVA > 5) and unresponsive to standard analgesics (level 1 or 2).
  3. Prior (< 3 months) immunosuppressive or corticosteroid therapy
  4. Additional cutaneous, and/or digestive and/or chronic renal diseases.
  5. HIV and B and C Chronic hepatitis
  6. Pregnancy or breast feeding or women without sufficient contraception among women of childbearing
  7. Known allergy or intolerance to study medication or any of its excipients (lactose, saccharose)
  8. Contraindication to colchicine such as:

    • severe hepatic insufficiency
    • combination with a macrolide (except spiramycin),
    • combination with pristinamycin
  9. Participation in another interventional trial
  10. Patient having not signed an informed consent
  11. Patient without Social Security System Insurance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04008316


Contacts
Layout table for location contacts
Contact: Evangeline PILLEBOUT, MD +33 1 42 49 96 05 evangeline.pillebout@aphp.fr
Contact: Alexandra AUDMARD-VERGER, MD +33 2 31 06 45 79 alexandra.audemard-verger@chu-caen.fr

Locations
Layout table for location information
France
Saint Louis Hospital
Paris, France, 75010
Contact: Evangeline PILLEBOUT, MD    +33 1 42 49 96 053    evangeline.pillebout@aphp.fr   
Contact: Alexandra AUDMARD-VERGER, MD    +33 2 31 06 45 79    alexandra.audemard-verger@chu-caen.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Evangeline PILLEBOUT, MD APHP
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04008316    
Other Study ID Numbers: P170910J
2018-002114-13 ( EudraCT Number )
First Posted: July 5, 2019    Key Record Dates
Last Update Posted: November 18, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Colchicine
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents